JR Research is an opportunistic investor. He was recognized by TipRanks as a Top Analyst. He was also recognized by Seeking Alpha as a "Top Analyst To Follow" for Technology, Software, and Internet, as well as for Growth and GARP. He identifies attractive risk/reward opportunities supported by robust price action to potentially generate alpha well above the S&P 500. He has also demonstrated outperformance with his picks. He focuses on identifying growth investing opportunities that present the most attracti ...

Bagsværd, Denmark, 21 October 2024 — Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomised trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). The trial enrolled 9,650 people with type 2 diabetes and established cardiovascular disease (CVD) and/or chronic kidney disease (CKD). As part of standard of care, 49% of patients received SGLT2i at some po ...

Bagsværd, Denmark, 18 October 2024 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending approval of Alhemo® (concizumab) as the first once-daily subcutaneous prophylactic treatment for people aged 12 years or older living with haemophilia A or B with inhibitors. Haemophilia is a rare bleeding disorder that impairs the body’s ability to make blood clots, a process needed to stop bleeding. H ...

Core Insights - Novo Resources Corp. has released its 2024 Sustainability Report, highlighting its commitment to sustainability and the importance of stakeholder engagement, including local communities and traditional owners [1][2]. Company Overview - Novo Resources Corp. is an Australian-based gold explorer listed on the ASX and TSX, focusing on discovering standalone gold projects with over 1 million ounces (Moz) development potential [4]. - The company holds a significant land package of approximately 6,700 square kilometers in the Pilbara region of Western Australia, along with the 22 square kilometer Belltopper project in Victoria, Australia [4]. Recent Developments - Over the past year, Novo transitioned from an operator to a gold explorer, divesting the Nullagine Gold Project and completing multiple joint ventures (JVs) [2]. - The company is advancing its key project area, the Egina Gold Camp, where it has formed a JV with De Grey Mining at the Becher Project, involving an exploration expenditure of A$25 million over four years for a 50% interest [5]. - Novo is also progressing gold exploration at Nunyerry North, part of the Croydon JV, where significant gold mineralization was identified in 2023 [5]. Strategic Focus - Novo has formed lithium joint ventures with Liatam and SQM in the Pilbara, providing exposure to battery metals for shareholders [5]. - The company maintains a disciplined program to identify value-accretive opportunities aimed at building further value for shareholders [5].

Novo Nordisk (NVO) closed the most recent trading day at $117.81, moving -1.64% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.76%. Elsewhere, the Dow lost 0.75%, while the tech-heavy Nasdaq lost 1.01%.The the stock of drugmaker has fallen by 12.51% in the past month, lagging the Medical sector's loss of 3.35% and the S&P 500's gain of 4.31%.Investors will be eagerly watching for the performance of Novo Nordisk in its upcoming earnings disclosure. The co ...

Novo Nordisk (NVO) ended the recent trading session at $117.20, demonstrating a -0.48% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of 0.97% for the day. At the same time, the Dow added 0.3%, and the tech-heavy Nasdaq gained 1.45%.The the stock of drugmaker has fallen by 10.72% in the past month, lagging the Medical sector's loss of 3.72% and the S&P 500's gain of 5.41%.Market participants will be closely following the financial results of Novo N ...

The initiative will launch in six cities across five continentsInterventions aim to increase physical activity and healthy eating among childrenThe three-year initiative comes with an investment of more than 250 million Danish kroner Bagsværd, Denmark, 8 October 2024 – Novo Nordisk today announced a new global initiative to prevent obesity in children. The Childhood Obesity Prevention Initiative aims to accelerate the prevention of childhood obesity in disadvantaged urban communities globally. Together wit ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________ FORM 6-K ________________ REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 September 30, 2024 ________________ NOVO NORDISK A/S (Exact name of Registrant as specified in its charter) Novo Allé 1 DK- 2880, Bagsvaerd Denmark (Address of principal executive offices) ________________ Indicate by check mark whether the registrant files or will file annual reports under ...

The thrust of the company's long-term strategy is becoming clearer.By now, pretty much everyone has heard of Novo Nordisk's (NVO -2.09%) widely popular drug for type 2 diabetes, Ozempic. And, as many investors appreciate, when a pharma company mints a winning product, it's only logical for it to leverage the expertise required to develop the product into making new medicines that are even better.On that note, Novo is already moving very aggressively to invent sequels to Ozempic by flexing its financial migh ...